公司代码：688192 公司简称：迪哲医药 迪哲（江苏）医药股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 3 月 | 2025 | 年第一次临时股东大会会议须知 2 | | --- | --- | | 2025 | 年第一次临时股东大会会议议程 4 | | 一、 | 关于延长向特定对象发行 A 股股票股东大会决议有效期的议案 6 | | 二、 | 关于提请股东大会延长授权董事会办理向特定对象发行 A 股股票相关 | 迪哲（江苏）医药股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权利，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则（2022 年修订）》以及《迪哲（江苏）医药股份有限 公司章程》《迪哲（江苏）医药股份有限公司股东大会议事规则》等相关规定， 迪哲（江苏）医药股份有限公司（以下简称"公司"）特制定 2025 年第一次临时 股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-08 迪哲（江苏）医药股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 3 月 25 日 14 点 30 分 召开地点：无锡市新吴区和风路 26 号汇融商务广场 C 栋 4 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 25 日 至 2025 年 3 月 25 日 1 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | A ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-07 迪哲（江苏）医药股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 迪哲（江苏）医药股份有限公司（以下简称"公司"）董事会于 2025 年 3 月 9 日召 开公司第二届董事会第十二次会议（以下简称"会议"）。本次会议通知于 2025 年 3 月 4 日以邮件方式送达董事，本次会议应到董事 7 人，实到董事 7 人。会议的召集、召开 程序以及召开方式符合相关法律法规以及《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一）审议通过《关于延长向特定对象发行 A 股股票股东大会决议有效期的议案》 董事发言要点与主要意见：无异议。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 此议案尚需提交公司 2025 年第一次临时股东大会审议。 （二）审议通过《关于提请股东大会延长授权董事会办理向特定对象发行 A 股 ...

Financial Performance - In 2024, the company achieved total operating revenue of 360.39 million yuan, a significant increase of 294.79% compared to the previous year[5] - The net loss attributable to the parent company was 856.77 million yuan, a reduction of 250.94 million yuan from the previous year[9] - The company’s basic earnings per share were -2.07 yuan, an improvement from -2.72 yuan in the previous year[5] - The weighted average return on net assets was -164.88%, down from -84.95% in the previous year[5] - The company’s equity attributable to shareholders decreased by 78.44% to 182.94 million yuan[5] Assets and Investments - The company’s total assets at the end of the reporting period were 1,718.86 million yuan, reflecting a 14.87% increase from the beginning of the period[5] - The company continues to invest heavily in R&D, with ongoing clinical trials for multiple products, including DZD8586 and DZD6008[9] Market Developments - The company’s core products, Shuwozhe® and Gaoruizhe®, were included in the National Medical Insurance Drug List, effective January 1, 2025, enhancing their market accessibility[7] - The company completed a price compensation for distributors due to significant price reductions after entering the National Medical Insurance Drug List, impacting Q4 sales[8] Future Outlook - The company expects to maintain a negative net profit situation due to high R&D expenditures despite significant revenue growth[10]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-05 迪哲（江苏）医药股份有限公司 关于向特定对象发行股票申请获得 中国证监会同意注册批复的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会出具的《关于同意迪哲（江苏）医药股份有限公司向特定对象 发行股票注册的批复》（证监许可〔2025〕171 号）（以下简称"批复文件"）， 批复文件内容如下： 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方 案实施。 三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及 时报告上海证券交易所并按有关规定处理。 公司董事会将按照上述批复文件和相关法律法规的要求以及公司股东大会 的授权，在规定期限内办理本次向特定对象发行股票的相关事项，并及时履行 信息披露义务，敬请广大投资者注意投资风险。 特此公告。 迪哲（江苏）医药股份 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [7]. Core Insights - The company is focused on developing innovative drugs with differentiated competitive advantages, particularly in the small molecule sector, and has a strong pipeline of products [7]. - The company has successfully commercialized its product Shuwotini in China and is on track for approval in the U.S. market, indicating strong growth potential [7]. - The report highlights the company's unique position in addressing unmet medical needs in oncology, particularly with its lead products targeting specific mutations in non-small cell lung cancer (NSCLC) [7]. Summary by Sections 1. Company Overview - The company was established in 2017 and went public in December 2021, focusing on innovative drug development with a global competitive edge [15]. - The management team has extensive experience in the pharmaceutical industry, enhancing the company's operational capabilities [15][18]. 2. Product Pipeline - The company has six products in its pipeline, with Shuwotini being the first globally to receive breakthrough therapy designation for treating EGFR Exon20ins NSCLC [7][15]. - Golixitinib is the first and only JAK1 inhibitor approved for treating relapsed/refractory peripheral T-cell lymphoma (PTCL) [7]. 3. Market Potential - The report estimates that the global market for EGFR Exon20ins NSCLC patients will grow, with new cases expected to reach 74,000 by 2024 and 86,000 by 2030 [7][32]. - The domestic sales forecast for Shuwotini is projected to reach approximately 4 billion RMB in 2024, with significant growth expected in subsequent years [7]. 4. Financial Projections - The company anticipates peak sales for its four products to reach nearly 6 billion RMB by 2032, with a target stock price of 82.26 RMB per share based on discounted cash flow analysis [7]. - The report provides detailed revenue forecasts, indicating a substantial increase in total revenue from 91.29 million RMB in 2023 to 1.2 billion RMB by 2026 [7]. 5. Commercialization Strategy - The company has established a comprehensive commercialization strategy, including a nationwide sales network and plans for international expansion [29]. - Shuwotini and Golixitinib have been included in the national medical insurance directory, effective January 1, 2025, which is expected to enhance their market penetration [29].

证券代码：688192 证券简称：迪哲医药 公告编号：2025-04 迪哲（江苏）医药股份有限公司 关于董事兼高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 重要内容提示： 董事持股的基本情况： 截至本公告披露日，迪哲（江苏）医药股份有限公司（以下简称"公司"） 董事长兼首席执行官张小林（ZHANG XIAOLIN）博士直接持有公司股份 7,310,972 股，占公司总股本的 1.7505%，上述股份来源包括股权激励计划行权 及二级市场增持。 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延。 （一）相关股东是否有其他安排 □是 √否 （二）大股东董监高此前对持股比例、持股数量、持股期限、减持方式、减持 数量、减持价格等是否作出承诺 √是 □否 减持计划的主要内容： 张小林博士因偿还借款等个人资金需求，拟通过集中竞价或大宗交易方式 合计减持不超过 1,827,000股（含本数），占公司总股本的比例不超过 0.4374%， 占其本人本次减持前所持有公司股份 ...

Core Viewpoint - Dizh Medical (688192.SH) has announced a projected net loss for the year 2024, despite an expected significant increase in revenue compared to the previous year [1][2]. Financial Performance - The company anticipates a revenue of approximately 360 million yuan for 2024, which represents an increase of about 294.35% compared to the previous year [1]. - Research and development expenses are expected to be around 738 million yuan, reflecting a decrease of approximately 8.39% year-on-year [1]. - The projected net loss attributable to the parent company is around 865 million yuan, which is a reduction of about 21.91% compared to the previous year [1]. - The net loss after excluding non-recurring items is expected to be approximately 918 million yuan, also showing a decrease of about 20.91% year-on-year [1]. Historical Context - In 2023, Dizh Medical reported a revenue of approximately 91.29 million yuan and a net loss of 1.108 billion yuan, which was an increase in loss from 736 million yuan in the previous year [2]. - The company has been operating at a net cash flow deficit from operating activities, with a net cash flow of -968 million yuan in 2023, compared to -603 million yuan in the previous year [2]. Stock and Financing Information - Dizh Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, with an initial issuance of 40 million shares at a price of 52.58 yuan per share [3]. - The stock is currently trading below its initial offering price, indicating a state of "broken issue" [4]. - The total funds raised from the initial public offering amounted to 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs [5]. - The company plans to raise up to 1.848 billion yuan through a private placement of A-shares, which will be used for new drug research and development, international standard innovative drug industrialization projects, and to supplement working capital [7][8]. Shareholding Structure - Dizh Medical has no controlling shareholder or actual controller, with a relatively dispersed shareholding structure [9]. - AstraZeneca AB and Advanced Manufacturing Industry Investment Fund (Limited Partnership) are the largest shareholders, each holding 26.69% of the company's shares as of the reporting period [9].

Revenue Projections - The company expects to achieve approximately CNY 360 million in revenue for 2024, an increase of about CNY 268.71 million or 294.35% year-on-year[3]. - The company anticipates a revenue impact of approximately CNY 52 million due to price adjustments following the inclusion in the National Medical Insurance Drug List[5]. R&D Expenses and Progress - The estimated R&D expenses for 2024 are around CNY 738 million, a decrease of approximately CNY 67.60 million or 8.39% compared to the previous year[3]. - The company’s core product Shuwozhe® has received priority review from the FDA for a new drug application, indicating ongoing R&D progress[6]. - The company is actively conducting multiple clinical studies for its products, including DZD8586 and DZD6008, indicating a robust pipeline[6]. Net Loss Projections - The projected net loss attributable to the parent company for 2024 is approximately CNY 865 million, a reduction of about CNY 242.71 million or 21.91% year-on-year[3]. - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be around CNY 918 million, a decrease of approximately CNY 242.73 million or 20.91% year-on-year[3]. Product Approvals and Market Access - The company’s second core product, Gao Ruizhe®, received approval for market launch in June 2024, contributing to significant revenue growth[4]. - Both Shuwozhe® and Gao Ruizhe® have been included in the National Medical Insurance Drug List, effective January 1, 2025, enhancing their market accessibility[4]. Performance Forecast Accuracy - The company confirms that there are no significant uncertainties affecting the accuracy of this performance forecast[7].

证券代码：688192 证券简称：迪哲医药 公告编号：2025-01 迪哲（江苏）医药股份有限公司 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 57,451,788 股。 本次股票上市流通总数为 57,451,788 股。 本次股票上市流通日期为 2025 年 1 月 9 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 3 日出具的《 关于同意迪哲《 江 苏）医药股份有限公司首次公开发行股票注册的批复》 证监许可〔2021〕3494 号），迪哲《 江苏）医药股份有限公司《 以下简称"公司"）首次向社会公开发行人 民币普通股 A 股）40,000,100 股，并于 2021 年 12 月 10 日在上海证券交易所科 创板上市。发行完成后公司总股本为 400,000,100 股，其中有限售条件流通股 363,050,516 股，无限售条件流通股为 36,949,584 股。 本次上市流通的限售股为公司首次公开发行前部分股东持有的限售股，涉及 1 名限售股股东，为江苏无锡迪喆企业管理合伙企业 有限合伙） 以下简称"无锡 迪喆"），持有限售 ...